Trials / Completed
CompletedNCT05866315
The Effect of Remimazolam on Opioid Induced Hyperalgesia
The Effect of Remimazolam on Remifentanil-induced Hyperalgesia
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Wonkwang University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this prospective, randomized, controlled study is to investigate the effect of remimazolam on opioid-induced hyperalgesia (OIH) in patients undergoing single port-laparoscopically assisted urologic surgery. The main question\[s\] it aims to answer are: * \[The mechanical hyperalgesia threshold\] * \[Area of hyperalgesia around the surgical incision 24 h after surgery (cm\^2)\] In three groups: Group RHR (Remimazolam- High-dose Remifentanil), Group DHR (Desflurane-low-dose Remifentanil) or Group DLR (Control).
Detailed description
Ninety-three (n = 31 per group) American Society of Anesthesiologists I-II patients (age 20-65 years) will be scheduled for single port-laparoscopically assisted urologic surgery. Group RHR (Remimazolam-Remifentanil): Administer remimazolam at a dose of 6 mg/kg/h initially, followed by 1 mg/kg/h, and remifentanil at 0.3 µg/kg/min. Group DHR (Desflurane-Remifentanil): Administer desflurane at 1 minimum alveolar concentration (MAC), adjusting the dose by 1 vol% titration to maintain MAP and BIS levels, and remifentanil at 0.3 µg/kg/min. Group DLR (Control): Administer desflurane at 1 MAC, adjust the dose by 1 vol% titration to maintain mean arterial pressure (MAP) and bispectral index (BIS) levels, and remifentanil at 0.3 µg/kg/min. Mechanical hyperalgesia threshold, Time to first postoperative analgesic requirement (min), Injected PCA volume containing morphine for 12 h after surgery (ml), Pain intensity: VAS 1 h after surgery, VAS 6 h after surgery, VAS 12 h after surgery VAS 24 h after surgery. Area of hyperalgesia around the surgical incision 24 h after surgery (cm\^2) will be checked.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam | Administer remimazolam |
| DRUG | Desflurane | administer desflurane |
| DRUG | Remifentanil | administer remifentanil |
Timeline
- Start date
- 2023-05-19
- Primary completion
- 2023-09-06
- Completion
- 2023-09-15
- First posted
- 2023-05-19
- Last updated
- 2023-10-06
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05866315. Inclusion in this directory is not an endorsement.